questionsmedicales.fr
Thérapeutique
Traitement médicamenteux
Traitement par apport liquidien
Traitement par apport liquidien : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Traitement par apport liquidien : Questions médicales les plus fréquentes",
"headline": "Traitement par apport liquidien : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Traitement par apport liquidien : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-07",
"dateModified": "2025-05-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Traitement par apport liquidien"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Traitement médicamenteux",
"url": "https://questionsmedicales.fr/mesh/D004358",
"about": {
"@type": "MedicalCondition",
"name": "Traitement médicamenteux",
"code": {
"@type": "MedicalCode",
"code": "D004358",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.319"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Hypodermoclyse",
"alternateName": "Hypodermoclysis",
"url": "https://questionsmedicales.fr/mesh/D055103",
"about": {
"@type": "MedicalCondition",
"name": "Hypodermoclyse",
"code": {
"@type": "MedicalCode",
"code": "D055103",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.319.360.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Traitement par apport liquidien",
"alternateName": "Fluid Therapy",
"code": {
"@type": "MedicalCode",
"code": "D005440",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Robert G Hahn",
"url": "https://questionsmedicales.fr/author/Robert%20G%20Hahn",
"affiliation": {
"@type": "Organization",
"name": "Department of Clinical Sciences at Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Amy K Keir",
"url": "https://questionsmedicales.fr/author/Amy%20K%20Keir",
"affiliation": {
"@type": "Organization",
"name": "Department of Neonatal Medicine, Women's and Children's Hospital, North Adelaide, South Australia; SAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, South Australia; Adelaide Medical School and the Robinson Research Institute, University of Adelaide, Adelaide, South Australia. Electronic address: amy.keir@adelaide.edu.au."
}
},
{
"@type": "Person",
"name": "Matthew W Semler",
"url": "https://questionsmedicales.fr/author/Matthew%20W%20Semler",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University, Nashville, Tennessee, USA."
}
},
{
"@type": "Person",
"name": "Matthias Jacob",
"url": "https://questionsmedicales.fr/author/Matthias%20Jacob",
"affiliation": {
"@type": "Organization",
"name": "Department of Anesthesiology and Surgical Intensive Care, St. Elisabeth Hospital, Straubing, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?",
"datePublished": "2023-02-03",
"url": "https://questionsmedicales.fr/article/36718727",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14737140.2023.2171991"
}
},
{
"@type": "ScholarlyArticle",
"name": "The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men.",
"datePublished": "2023-05-02",
"url": "https://questionsmedicales.fr/article/37534902",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4103/aja20239"
}
},
{
"@type": "ScholarlyArticle",
"name": "Simultaneous thulium laser resection of the prostate and transperineal prostate biopsy in clinically diagnosed metastatic prostate cancer with bladder outlet obstruction.",
"datePublished": "2023-08-18",
"url": "https://questionsmedicales.fr/article/37596454",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10103-023-03848-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Staging Prostate Cancer with",
"datePublished": "2023-04-28",
"url": "https://questionsmedicales.fr/article/37116912",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2967/jnumed.122.265371"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostate MRI Qualification:",
"datePublished": "2022-05-11",
"url": "https://questionsmedicales.fr/article/35544372",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2214/AJR.22.27615"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Thérapeutique",
"item": "https://questionsmedicales.fr/mesh/D013812"
},
{
"@type": "ListItem",
"position": 3,
"name": "Traitement médicamenteux",
"item": "https://questionsmedicales.fr/mesh/D004358"
},
{
"@type": "ListItem",
"position": 4,
"name": "Traitement par apport liquidien",
"item": "https://questionsmedicales.fr/mesh/D005440"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Traitement par apport liquidien - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Traitement par apport liquidien",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Traitement par apport liquidien",
"description": "Comment diagnostiquer une déshydratation ?\nQuels tests sont utilisés pour évaluer l'hydratation ?\nQuels signes indiquent un besoin de traitement liquidien ?\nComment évaluer l'équilibre électrolytique ?\nQuels sont les critères de gravité de la déshydratation ?",
"url": "https://questionsmedicales.fr/mesh/D005440?mesh_terms=Prostatic+Neoplasms&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Traitement par apport liquidien",
"description": "Quels sont les symptômes de la déshydratation ?\nComment reconnaître une hyperhydratation ?\nQuels symptômes nécessitent une attention médicale ?\nQuels sont les signes de déséquilibre électrolytique ?\nComment la déshydratation affecte-t-elle la performance physique ?",
"url": "https://questionsmedicales.fr/mesh/D005440?mesh_terms=Prostatic+Neoplasms&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Traitement par apport liquidien",
"description": "Comment prévenir la déshydratation ?\nQuels aliments aident à maintenir l'hydratation ?\nComment éviter l'hyperhydratation ?\nQuels conseils pour les sportifs en période de chaleur ?\nComment adapter l'hydratation en cas de maladie ?",
"url": "https://questionsmedicales.fr/mesh/D005440?mesh_terms=Prostatic+Neoplasms&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Traitement par apport liquidien",
"description": "Quels types de fluides sont utilisés en thérapie liquidienne ?\nComment administrer des liquides par voie orale ?\nQuand utiliser une perfusion intraveineuse ?\nQuels sont les risques d'une surhydratation ?\nComment surveiller l'efficacité du traitement liquidien ?",
"url": "https://questionsmedicales.fr/mesh/D005440?mesh_terms=Prostatic+Neoplasms&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Traitement par apport liquidien",
"description": "Quelles complications peuvent survenir avec une déshydratation sévère ?\nQuels sont les effets d'une surhydratation prolongée ?\nComment la déshydratation affecte-t-elle les organes ?\nQuels sont les risques d'une perfusion mal administrée ?\nQuelles sont les conséquences d'un traitement liquidien inapproprié ?",
"url": "https://questionsmedicales.fr/mesh/D005440?mesh_terms=Prostatic+Neoplasms&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Traitement par apport liquidien",
"description": "Quels facteurs augmentent le risque de déshydratation ?\nComment les maladies affectent-elles l'hydratation ?\nQuel rôle joue l'exercice dans l'hydratation ?\nComment l'alimentation influence-t-elle l'hydratation ?\nQuels médicaments peuvent affecter l'hydratation ?",
"url": "https://questionsmedicales.fr/mesh/D005440?mesh_terms=Prostatic+Neoplasms&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déshydratation ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La déshydratation est diagnostiquée par des signes cliniques et des tests sanguins."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'hydratation ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'analyse sanguine, l'urine et l'évaluation clinique des symptômes."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent un besoin de traitement liquidien ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent soif intense, sécheresse de la peau, fatigue et confusion."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'équilibre électrolytique ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'équilibre électrolytique est évalué par des tests sanguins mesurant les niveaux d'électrolytes."
}
},
{
"@type": "Question",
"name": "Quels sont les critères de gravité de la déshydratation ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent la perte de poids, la fréquence cardiaque et la pression artérielle."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de la déshydratation ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent soif, bouche sèche, fatigue, vertiges et urine foncée."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une hyperhydratation ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent œdème, hypertension, confusion et essoufflement."
}
},
{
"@type": "Question",
"name": "Quels symptômes nécessitent une attention médicale ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme confusion, convulsions ou perte de conscience nécessitent une urgence."
}
},
{
"@type": "Question",
"name": "Quels sont les signes de déséquilibre électrolytique ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent crampes musculaires, fatigue, palpitations et confusion mentale."
}
},
{
"@type": "Question",
"name": "Comment la déshydratation affecte-t-elle la performance physique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner une diminution de l'endurance, de la force et des temps de réaction."
}
},
{
"@type": "Question",
"name": "Comment prévenir la déshydratation ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est essentiel de boire régulièrement, surtout lors d'activités physiques ou par temps chaud."
}
},
{
"@type": "Question",
"name": "Quels aliments aident à maintenir l'hydratation ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les fruits et légumes riches en eau, comme la pastèque et le concombre, sont bénéfiques."
}
},
{
"@type": "Question",
"name": "Comment éviter l'hyperhydratation ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez de consommer trop de liquides en peu de temps, surtout lors d'activités intenses."
}
},
{
"@type": "Question",
"name": "Quels conseils pour les sportifs en période de chaleur ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les sportifs doivent s'hydrater avant, pendant et après l'exercice, en surveillant les signes de déshydratation."
}
},
{
"@type": "Question",
"name": "Comment adapter l'hydratation en cas de maladie ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Augmentez l'apport liquidien en cas de fièvre, vomissements ou diarrhée pour prévenir la déshydratation."
}
},
{
"@type": "Question",
"name": "Quels types de fluides sont utilisés en thérapie liquidienne ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les fluides intraveineux, comme les solutions salines et glucosées, sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Comment administrer des liquides par voie orale ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les liquides peuvent être administrés par gorgées fréquentes ou via des solutions de réhydratation."
}
},
{
"@type": "Question",
"name": "Quand utiliser une perfusion intraveineuse ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une perfusion est utilisée en cas de déshydratation sévère ou lorsque l'administration orale est impossible."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'une surhydratation ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent œdème pulmonaire, hypertension et déséquilibre électrolytique."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement liquidien ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est surveillée par l'évaluation des signes vitaux, de l'urine et des symptômes."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une déshydratation sévère ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent insuffisance rénale, choc hypovolémique et troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Quels sont les effets d'une surhydratation prolongée ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surhydratation prolongée peut entraîner des œdèmes, des troubles respiratoires et des déséquilibres électrolytiques."
}
},
{
"@type": "Question",
"name": "Comment la déshydratation affecte-t-elle les organes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des lésions rénales, des troubles cardiaques et des dysfonctionnements cérébraux."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'une perfusion mal administrée ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent infection, phlébite et déséquilibre électrolytique."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'un traitement liquidien inapproprié ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement inapproprié peut aggraver la déshydratation ou provoquer une surhydratation."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de déshydratation ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge avancé, les maladies chroniques et les conditions climatiques extrêmes."
}
},
{
"@type": "Question",
"name": "Comment les maladies affectent-elles l'hydratation ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies, comme le diabète, augmentent la perte de liquides et le risque de déshydratation."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'exercice dans l'hydratation ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'exercice intense augmente la perte de liquides, nécessitant une hydratation adéquate."
}
},
{
"@type": "Question",
"name": "Comment l'alimentation influence-t-elle l'hydratation ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation pauvre en eau et en électrolytes peut augmenter le risque de déshydratation."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent affecter l'hydratation ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains diurétiques et laxatifs peuvent augmenter le risque de déshydratation."
}
}
]
}
]
}
The paradigm of focal therapy's role in metastatic patients is being challenged by evolving attitudes and emerging data. At the current time, specifically regarding prostate cancer, does the evidence ...
We searched the literature via PubMed, MEDLINE, and Embase for studies from 2014 to the present addressing focal therapy with non-palliative intent in metastatic prostate cancer patients, emphasizing ...
Current evidence is strongest, and in our opinion practice-changing, for prostate-directed RT in de novo metastatic patients with low metastatic burden. Metastasis-directed therapy with SBRT is consis...
Using prostate-specific antigen (PSA) for prostate cancer (PCa) screening led to overinvestigation and overdiagnosis of indolent PCa. We aimed to investigate the value of prostate health index (PHI) a...
Metastatic prostate cancer (mPCa) patients complicated with bladder outlet obstruction (BOO) are often referred to a urologist. Androgen deprivation therapy (ADT) combined with indwelling catheter usu...
Although prostate-specific membrane antigen (PSMA) PET/CT has been shown valuable for staging biopsy-proven [B(+)] high-risk prostate cancer, elderly patients are occasionally referred for PSMA PET/CT...
Prostate MRI is now established as a first-line investigation for individuals presenting with suspected localized or locally advanced prostate cancer. Successful delivery of the MRI-directed pathway f...
Prostate cancer has a long disease history and a wide variety and uncertainty in individual patients' clinical progress. In recent years, we have seen a revolutionary advance in both prostate cancer p...
There is a clinical need to identify patients with an elevated PSA who would benefit from prostate biopsy due to the presence of clinically significant prostate cancer (CSCaP). We have previously repo...
To further develop and adapt the MiCheck® Prostate test so it can be performed using a standard clinical chemistry analyzer and characterize its performance using the MiCheck-01 clinical trial sample ...
About 358 patient samples from the MiCheck-01 US clinical trial were used for the development of the MiCheck® Prostate test. These consisted of 46 controls, 137 non-CaP, 62 non-CSCaP, and 113 CSCaP....
Serum analyte concentrations for cellular growth factors were determined using custom-made Luminex-based R&D Systems multi-analyte kits. Analytes that can also be measured using standard chemistry ana...
Logistic regression modeling with Monte Carlo cross-validation was used to identify Human Epidydimal Protein 4 (HE4) as an analyte able to significantly improve the algorithm specificity at 95% sensit...
The MiCheck® logistic regression model was developed and consisted of PSA, %free PSA, DRE, and HE4. The model differentiated clinically significant cancer from no cancer or not-clinically significant ...
The MiCheck® Prostate test identifies clinically significant prostate cancer with high sensitivity and negative predictive value (NPV). It can be performed in a clinical laboratory using a Roche Cobas...
Prostate health index (PHI) and, more recently, Proclarix have been proposed as serum biomarkers for prostate cancer (PCa). In this study, we aimed to evaluate Proclarix and PHI for predicting clinica...
Proclarix and PHI were measured using samples of 344 men from two different centers. All patients underwent prostate biopsy, and among those, 188 men with PCa on biopsy had an additional radical prost...
The cohort median age and PSA were 65 (interquartile range [IQR]: 60-71) and 5.6 (IQR: 4.3-7.2) ng/ml, respectively. CsPCa was diagnosed in 161 (47%) men based on the RP specimen. ROC analysis showed ...
Results of this study show that both Proclarix and PHI accurately detect the presence of csPCa. The model combining Proclarix and PHI revealed the synergistic effect and improved the diagnostic perfor...
Transperineal (TP) multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy (TBx) has been shown to detect more clinically significant (cs) prostate cancer (PCa) than standard template biops...
We identified all men who with suspicious lesions on mpMRI and underwent TP TBx (3-core) and concomitant SBx (20-core) in our single hospital from September 2019 to February 2021. Clinical, MRI and bi...
Three hundred and one (n = 301) men were included. The median prostate volume by MRI was 45 ml. The patients were divided by prostate volume into three groups: ≤30ml group (19.9%), >30 to ≤45 ml group...
Our data suggest that performing TBx with limited additional cores may potentially achieve the same csPCa detection rate as the combined SBx and TBx in smaller prostates....
We sought to determine whether two soluble forms with different size of mtDNA are linked to prostatic inflammation, and whether they discriminate prostate cancer (PCa) from inflammatory prostatic cond...
Histopathologically diagnosed prostatitis, PCa and benign prostatic hyperplasia patients (n = 93) were enrolled in this study and they were categorized as with and without prostate inflammation. Quant...
The urine mtDNA-79 and mtDNA-230 were significantly increased in patients with prostate inflammation compared with those in without inflammation. Here, 79-bp fragment of apoptotic origin was significa...
Our results demonstrate that shorter cf-mtDNA fragment size in particular, increase in the presence of prostate inflammation in post-prostatic massage urine but both fragments could never improve seru...